Libeitan Lecankitug Injection (Subcutaneous Injection)

1. Indications and Usage
Lecanemab-Irmb (Subcutaneous) is indicated for the treatment of patients with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) due to Alzheimer’s or mild dementia due to Alzheimer’s .
2. Dosage and Administration
Recommended Dose: The recommended dose is 500 mg administered once weekly as two separate subcutaneous injections (250 mg per injection).
Administration: It is administered by a healthcare professional or a caregiver. The autoinjector delivers the dose in approximately 15 seconds.
Missed Dose: If a dose is missed, administer it as soon as possible within 7 days. If more than 7 days have passed, wait until the next scheduled dose. Do not administer a double dose.
3. Mechanism of Action
Lecanemab is a humanized monoclonal antibody that binds with high specificity to soluble amyloid-β (Aβ) protofibrils. It also binds to Aβ aggregates (plaques). By clearing these toxic Aβ species, it aims to slow the progression of Alzheimer’s disease pathology .
4. Safety and Warnings
ARIA (Amyloid-Related Imaging Abnormalities): Lecantemab can cause ARIA, including ARIA-E (edema) and ARIA-H (microhemorrhage or hemosiderin deposition). Baseline and periodic brain MRIs are required.
Hypersensitivity: Severe hypersensitivity reactions (anaphylaxis) including infusion/injection site reactions, angioedema, and bronchospasm have occurred.
Contraindications: There are no known absolute contraindications, but caution is advised in patients with a history of severe hypersensitivity to the drug or its excipients.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: The most common adverse reactions (≥10%) include infusion/injection site reactions, ARIA-E, ARIA-H, headache, and falls.
Clinical Research: In the Phase 3 Clarity AD trial, weekly subcutaneous administration demonstrated comparable efficacy and safety to the IV regimen, with the majority of ADRs being mild-to-moderate local injection site reactions.
6. Drug Interactions
No formal drug interaction studies have been conducted. However, concomitant use with other immunosuppressants or drugs affecting the blood-brain barrier should be monitored. No dose adjustments are generally required for most concomitant medications.
7. Pharmaceutical Information
Active Ingredient: Lecanemab-irmb.
Appearance: Clear to opalescent, colorless to pale yellow liquid.
Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake.
Packaging: Pre-filled autoinjector (250 mg/1.25 mL).